People

Management & Governance

Centene earns a B governance grade: a refreshed, mostly independent board, rigorous pay-for-performance design that actually denied the 2023–2025 PSU cycle (0% payout), and an ISS QualityScore of 1 — but offset by a 2025 securities class action, a recurring history of state Medicaid pharmacy settlements, and a CEO who controls a Fortune 23 enterprise without meaningful founder-style ownership.

The People Running This Company

Centene's executive bench was rebuilt around the 2021 Politan Capital settlement. Long-time CEO Michael Neidorff exited in 2022; Sarah London, then 41 and the youngest woman ever to lead a Fortune 500 company, took the role. The team is technocratic — a mix of former managed-care operators (WellCare, Humana) and one ex-state-AG general counsel — but it is also unproven through a full earnings cycle, and 2025 was the first time it broke.

A separate April 6, 2026 announcement created two new Group President roles — Daniel Finke (Markets & Commercial) and Michael Carson (Medicare & Specialty) — both reporting to London. This is the first material structural change since the Marketplace blow-up, and reads as a defensive bench-deepening move rather than a succession signal.

What They Get Paid

CEO Sarah London's 2025 grant-date pay was $19.5M, virtually flat YoY. But under the SEC's "compensation actually paid" calculation — which marks equity to current stock price — she earned $4.6M, just 24% of her summary-table total. The 2023–2025 PSU cycle vested at 0% of target because none of the three metrics (pre-tax CAGR, net earnings margin, relative TSR) hit threshold. The pay machine, on this evidence, is genuinely performance-linked.

For 2026, the Compensation Committee took an unusual step: PSUs are now 100% absolute TSR, abandoning the financial-metric overlays. The committee's stated reason is the July 2025 stock collapse and resulting volatility. This is shareholder-friendly in spirit but concentrates the entire long-term incentive on a single, market-driven number — meaning a sector rerating could pay out enormously even if Centene operationally lags.

Are They Aligned?

This is where the picture gets mixed. The board has put real pay-at-risk and the CEO clears her 6× base ownership requirement comfortably. But there is no founder, no controlling promoter, no insider with a conviction position — the entire executive group as 14 people own less than 1% of the company.

Insider trading. Form 4 data shows zero open-market purchases and zero open-market sales in the last 12 months — every reported transaction is an RSU grant, vest, or tax withholding. No insider has stepped in to buy after the July 2025 stock collapse. This is not a red flag (insider open-window discipline is tight at large-cap healthcare), but it removes a strong alignment signal that founder-led peers often display.

Dilution. 11.7M options/RSUs outstanding plus 13.7M available for future issuance (roughly 5.2% of shares outstanding combined). No options have been granted since 2021. Net dilution from equity comp has been modest given the company's $176B revenue base.

Capital allocation behavior. Centene repurchased $3B of stock in 2024 and guided another $2B for 2025, executed under London/Asher. Buybacks above the 2025 collapse will look poor in hindsight; the Q4 2025 transcript shows the company has paused aggressive buybacks pending earnings restoration.

Related-party transactions. One material item: Director Kenneth Burdick served as Executive Chairman of LifeStance Health Group through March 14, 2026. Centene continued paying LifeStance for behavioral health services in 2025 under contracts that pre-dated his role. The board treats him as non-independent for this reason. Also disclosed: one executive officer has a family member employed by Centene earning over $120K. Neither item appears economically large, but Burdick is a 2.2-year board member from the Politan slate — his independence loss is not optics, it's substantive.

Skin-in-the-game = 6/10. Adds: rigorous PSU design that actually pays zero, 6× CEO ownership requirement met, double-trigger CIC, clawback policy, no hedging or pledging, no excise tax gross-ups. Subtracts: no founder/promoter, total insider ownership well under 1%, no open-market buys after the July 2025 collapse, $3B in 2024 buybacks above the eventual stock plunge, ongoing securities class action.

Board Quality

Six of nine directors joined in the last five years — a deliberate refresh that followed the December 2021 Politan Capital activist settlement, which forced five new directors and Neidorff's exit. The chair is independent (Frederick Eppinger, on the board since 2006). The audit chair is a former Prudential CFO. The compensation chair is a former Tyco CFO. Average age is 64; the mandatory retirement age of 75 means three directors will roll off within five years, requiring continued refresh discipline.

Expertise present: insurance/healthcare operations (Eppinger, Burdick, Dallas), audit/CFO (Tanji, Coughlin, Blume), technology (Ford, Dallas), capital allocation (Samuels). Expertise thin: clinical/medical practice — there is no physician or clinical operator on the board, unusual for a $176B managed-care company. The Quality Committee depends on operator perspective rather than clinical depth.

What worked in 2025. Compensation Committee defended the 0% PSU payout. The Audit Committee, chaired by a fresh-from-Prudential CFO, retained KPMG (auditor since 2005 — long tenure is a mild concern). The board chose to separate chair/CEO and to stagger refresh.

What failed. Risk oversight on Marketplace morbidity. Management told investors in July 2025 the 2025 risk pool had shifted "seismically" — a one-off external shock by Centene's account, but a securities class action has been filed alleging earlier knowledge. Until that resolves, board risk-oversight quality cannot be cleanly graded.

The Verdict

Strongest positives. ISS QualityScore = 1. Independent chair separated from CEO. PSU plan paid 0% to NEOs in 2025 — design has teeth. No poison pill, proxy access at 3%/3-yr, double-trigger CIC, clawback in place, hedging/pledging banned. Six of nine directors are fresh post-Politan, and the audit chair is a current-era insurance-industry CFO.

Real concerns. Securities class action over the July 2025 disclosure timing is unresolved. The 2026 PSU shift to 100% absolute TSR is a defensible response to volatility but removes financial-metric guardrails. Burdick's LifeStance related-party means one of nine directors is officially non-independent. Insider ownership in aggregate is below 1%, with zero open-market purchases since the stock collapse — alignment is contractual, not conviction-based.

The single thing that would move the grade. An adverse ruling or large settlement on the 2025 securities class action would push to C+/B-. Conversely, a clean dismissal combined with one or more NEOs making a six-figure open-market buy at current prices would push to B+ by establishing both legal closure and conviction alignment. Watch the Q1 2026 10-Q legal proceedings note.